Uses
Ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.
Source: US FDA prescribing information
Molecule
Ergocalciferol
Provitamin D2 Compound
Available on request
- Presentations
- 2
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Ergocalciferol is a provitamin D2 compound indicated in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia. It is available as capsules for oral use. MedsAcross supplies Ergocalciferol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Provitamin D2 Compound
- ATC classification
- A11CC01 Ergocalciferol · Vitamin D receptor modulator
- US FDA first approval
- 11 January 1941
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Oral
- Dosage forms
- Capsule
- Identifiers
- UNII VS041H42XCRxCUI 4018CAS 50-14-6DrugBank DB00153Q139200
Clinical information
From the regulator-approved product information. Each section names its source.
Dosing overview
THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. Vitamin D Resistant Rickets: 12,000 to 500,000 IU units daily. Hypoparathyroidism: 50,000 to 200,000 IU units daily concomitantly with calcium lactate 4 g, six times per day. DOSAGE MUST BE INDIVIDUALIZED UNDER CLOSE MEDICAL SUPERVISION. Calcium intake should be adequate. Blood calcium and phosphorus determinations must be made every 2 weeks or more frequently if necessary. X-rays of the bones should be taken every month until condition is corrected and stabilized.
Source: US FDA prescribing information
Contraindications
Ergocalciferol is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.
Source: US FDA prescribing information
Warnings and precautions
Hypersensitivity to vitamin D may be one etiologic factor in infants with idiopathic hypercalcemia. In these cases vitamin D must be strictly restricted. Keep out of the reach of children.
Source: US FDA prescribing information
Side effects
Hypervitaminosis D is characterized by effects on the following organ system: Renal: Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. CNS: Mental retardation. Soft Tissues: Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Skeletal: Bone demineralization (osteoporosis) in adults occurs concomitantly. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism) vague aches, stiffness, and weakness. Gastrointestinal: Nausea, anorexia, constipation. Metabolic: Mild acidosis, anemia, weight loss.
Source: US FDA prescribing information
Interactions
Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations. Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.
Source: US FDA prescribing information
Storage
Store at 77°F (25°C), excursions permitted between 59° to 86°F (15° to 30°C).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
2 presentations of Ergocalciferol, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ergocalciferol 1.25 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Vitamin D 1.25 mg capsuleOral | Strides PharmaIndia | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Indian manufacturers are highlighted.
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 11 January 1941 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions
Conditions linked to Ergocalciferol in public data. This is not a list of approved uses, see the clinical information.
Questions and answers
Is Ergocalciferol available for export from India?
Yes, on request. MedsAcross lists 2 presentations of Ergocalciferol and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Strides Pharma.
What brand names does Ergocalciferol have?
The catalogue lists 1 brand names for Ergocalciferol, including Vitamin D.
Is Ergocalciferol approved by the US FDA?
Yes. The US FDA first approved Ergocalciferol on 11 January 1941, according to Drugs@FDA.
Does Ergocalciferol need cold chain shipping?
No listed presentation of Ergocalciferol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Ergocalciferol in?
Ergocalciferol is classified under ATC code A11CC01 (Ergocalciferol).
References
- ERGOCALCIFEROL prescribing information (Torrent Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 4 September 2026
Request Ergocalciferol for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.